Moderna’s Spikevax and Pfizer’s Comirnaty are available for those 12-years and older at GIANT and MARTAIN’S pharmacies.

Moderna Inc. said Thursday a Phase 3 trial of its next-generation COVID-19 vaccine met its main goal and showed higher ...

Novavax's traditional protein-based shot offers an alternative vaccine technology to those that are based on messenger RNA - Moderna's Spikevax and Comirnaty, which is jointly developed by Pfizer ...

Moderna's Spikevax KP.2 targets the KP.2 variant of the virus. The U.S. Food and Drug Administration has also approved the shot, as well as updated vaccines from Pfizer and BioNTech. Moderna (MRNA ...

Spikevax 2024-2025 formula expected to be available in pharmacies and care settings across the U.S. in the days immediately following approval CAMBRIDGE, MA / ACCESSWIRE / August 22, 2024 ...

Those bandaids you stuffed in your pack aren’t going to cut it if you get a nasty ankle ... you can relieve their pain with burn gel, SuperSkin blister strips, or aspirin. This pouch comes in handy ...

Moderna developed the Spikevax COVID-19 vaccine, and regulators approved this year its vaccine for RSV or respiratory syncytial virus. The company also has a combination flu/COVID vaccine and an ...

On the heels of the nation’s biggest summer COVID surge—test positivity peaked at 17.8% the week ended Aug. 10—help has arrived. The 2024–25 coronavirus vaccines, initially anticipated ...

Image Source: Zacks Investment Research Spikevax, targeting the variant JN.1., is currently approved in the United States, the United Kingdom, Japan and Taiwan. Last month, the FDA approved ...

Stack Packs are a Membership option that features fan-favorite games. Save money, secure interest-free payment plans and get exclusive Member perks. Packs for the 2024-25 season are available now!

Both Spikevax (Moderna) and Comirnaty (Pfizer) vaccines have been updated. While the vaccine is targeted toward those 12 and over, children age six months through 11 years are also eligible for ...

Until now, Canada has only had access to vaccine formulas that were approved in fall 2023 and target the Omicron XBB.1.5. Moderna's latest formulation of their mRNA vaccine, Spikevax, targets the KP.2 ...